Eisai's Halaven First Breast Cancer Therapy for Which Price Negotiations with the National Association of Statutory Health Insurance Funds were Successfully Concluded

Eisai's Halaven First Breast Cancer Therapy for Which Price Negotiations with the National Association of Statutory Health Insurance Funds were Successfully Concluded PR Newswire FRANKFURT and HATFIELD, England, October 15, 2012 FRANKFURT and HATFIELD, England, October 15, 2012 /PRNewswire/ -- Price agreement endorses confidence in new treatment Eisai announced today that it concluded an agreement with the National Association of Statutory Health Insurance ®Funds (GKV-Spitzenverband) in Germany on a reimbursement price for Halaven (eribulin). According to its European ®licence Halaven is to be used for the treatment of patients with locally advanced or metastatic breast cancer whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have [1]included an anthracycline and a taxane unless patients were not suitable for these treatments. "We are delighted to have reached an agreement on the reimbursement price of Halaven with the GKV-SV. This is positive news as the price agreement provides confidence for payers and most importantly for physicians treating seriously ill women with metastatic or locally advanced breast cancer. Our negotiations have provided further evidence that a balance between the interests of pharmaceutical manufacturers and health insurance funds can be met, and can help generate savings for the German healthcare system," said Georg Wager, Director Market Access, Eisai, Europe Central.